ArticleJAMA network open2026
Social Determinants of Health and 1-Year Buprenorphine Initiation Among Justice-Involved Veterans.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Posttraumatic Stress Disorder, Health-Related Social Needs, and Cognitive Outcomes in US Veterans.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Importance: Justice-involved veterans (JIVs), with incarceration history or other legal involvement, experience high opioid use disorder (OUD) rates but low uptake of medications for OUD (MOUD). Given its common use, assessing the associations of buprenorphine medication for OUD (hereafter buprenorphine) with social determinants of health (SDOH) is critical. Objective: To assess the association between SDOH and buprenorphine initiation, and to estimate the 1-year initiation rate across demographic subgroups. Design, Setting, and Participants: This nested case-control study obtained data from the Veterans Health Administration (VHA) national electronic health record system. JIVs with an OUD diagnosis receiving VHA care between fiscal years 2015 and 2020 were included. Cases were OUD episodes with buprenorphine initiation, which were matched 1:4 with control episodes without initiation. The unit of analysis was the OUD episode, a period of 1 year following initial OUD diagnosis. Data analyses were conducted in August 2025. Exposures: Exposure to defined SDOH domains from the index date (first OUD diagnosis) until buprenorphine initiation date, 365 days after index date, or study end date, whichever occurred first, compared with no exposure. Main Outcomes and Measures: The primary outcomes were the 1-year buprenorphine initiation rate and the association of SDOH with initiation. Conditional logistic regression adjusted for clinical and demographic covariates was used to estimate adjusted odds ratios (AORs) and 95% CIs for the association between buprenorphine initiation and 8 domains of SDOH extracted from structured data and unstructured clinical notes. Results: Among 13 321 new OUD episodes in 12 511 JIVs, 1372 were case episodes (involving 1279 male JIVs [93.2%]; mean [SD] age, 40.8 [12.8] years) matched with 5436 control episodes (involving 5334 male JIVs [98.1%]; mean [SD] age, 39.2 [12.1] years). The 1-year buprenorphine initiation rate was 11.16% (95% CI, 10.63-11.71). Among SDOH domains identified from combined structured and unstructured data, violence (AOR, 0.31; 95% CI, 0.25-0.38), nonspecific psychosocial problems (AOR, 0.35; 95% CI, 0.30-0.40), food insecurity (AOR, 0.36; 95% CI, 0.30-0.44), and transitions of care (AOR, 0.50; 95% CI, 0.35-0.71) were associated with lower odds of buprenorphine initiation. Additional factors included barriers to care (AOR, 0.54; 95% CI, 0.45-0.64), financial problems (using structured data: AOR, 0.33; 95% CI, 0.28-0.40), and social problems (using structured data: AOR, 0.58; 95% CI, 0.44-0.79). Conclusions and Relevance: This case-control study found that buprenorphine initiation remained low and that multiple SDOH domains acted as significant barriers to treatment uptake among JIVs. The findings emphasize the importance of systematic SDOH screening and interventions to address barriers to buprenorphine initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.